NASDAQ:ITRM Iterum Therapeutics (ITRM) Stock Price, News & Analysis $0.03 0.00 (0.00%) As of 11/6/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsInsider TradesNews and TrendsOwnershipSEC Filings About Iterum Therapeutics Stock (NASDAQ:ITRM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Iterum Therapeutics alerts:Sign Up Key Stats Today's Range$0.03▼$0.0350-Day Range$0.03▼$0.0352-Week Range$0.03▼$1.42VolumeN/AAverage Volume4.85 million shsMarket Capitalization$1.60 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingReduce Company Overview Iterum Therapeutics plc is a pharmaceutical company focused on developing and commercializing antibiotics for bacterial infections, including infections caused by drug-resistant pathogens. The company is headquartered in Ireland and has focused its commercial efforts on the U.S. market. Its lead product is sulopenem, a penem-class antibiotic developed in oral and intravenous formulations. The oral formulation, marketed as Orlynvah, combines sulopenem etzadroxil with probenecid. In October 2024, the U.S. Food and Drug Administration approved Orlynvah for certain uncomplicated urinary tract infections in adult women who have limited or no alternative oral antibacterial treatment options. The approval marked a key step in Iterum’s efforts to bring its antibiotic to patients.AI Generated. May Contain Errors. Read More Receive ITRM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Iterum Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ITRM Stock News HeadlinesHC Wainwright & Co. downgrades Iterum Therapeutics (ITRM)March 31, 2026 | msn.comWhat's going on with Iterum Therapeutics stock Monday?March 30, 2026 | msn.comEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.November 18 at 1:00 AM | Behind the Markets (Ad)Iterum files wind-up petition due to limited cash, inability to raise equityMarch 27, 2026 | reuters.comIterum Therapeutics Announces Filing of Winding Up PetitionMarch 27, 2026 | globenewswire.comIterum Therapeutics (ITRM) price target increased by 63.64% to 9.18March 27, 2026 | msn.comIterum Therapeutics Provides Business UpdateFebruary 13, 2026 | globenewswire.comIterum Therapeutics PLCJanuary 17, 2026 | barrons.comSee More Headlines ITRM Stock Analysis - Frequently Asked Questions How have ITRM shares performed this year? Iterum Therapeutics' stock was trading at $0.3350 at the beginning of 2026. Since then, ITRM shares have decreased by 91.0% and is now trading at $0.03. How were Iterum Therapeutics' earnings last quarter? Iterum Therapeutics PLC (NASDAQ:ITRM) posted its quarterly earnings data on Friday, November, 14th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.13) by $0.07. The company earned $390 thousand during the quarter. Read the conference call transcript. When did Iterum Therapeutics' stock split? Iterum Therapeutics's stock reverse split on the morning of Thursday, August 18th 2022.The 1-15 reverse split was announced on Thursday, August 18th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Iterum Therapeutics IPO? Iterum Therapeutics (ITRM) raised $92 million in an initial public offering (IPO) on Friday, May 25th 2018. The company issued 6,150,000 shares at $14.00-$16.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers. What other stocks do shareholders of Iterum Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Iterum Therapeutics investors own include Atossa Genetics (ATOS), SNDL (SNDL), Tonix Pharmaceuticals (TNXP), NVIDIA (NVDA), NIO (NIO), 9 Meters Biopharma (NMTR) and Ideanomics (IDEX). Company Calendar Today11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (16m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 ITRM's financial health is in the Red zone, according to TradeSmith. ITRM has been in this zone for over 16 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ITRM CIK1659323 Webwww.iterumtx.com Phone(531) 669-4820FaxN/AEmployees10Year Founded2015Profitability EPS (Trailing Twelve Months)($0.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$24.77 million Net MarginsN/A Pretax Margin-6,842.31% Return on EquityN/A Return on Assets-65.54% Debt Debt-to-Equity RatioN/A Current Ratio2.13 Quick Ratio1.96 Sales & Book Value Annual Sales$390 thousand Price / Sales4.10 Cash FlowN/A Price / Cash FlowN/A Book Value($0.15) per share Price / Book-0.20Miscellaneous Outstanding Shares53,292,000Free Float52,226,000Market Cap$1.60 million OptionableNot Optionable Beta2.96 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:ITRM) was last updated on 11/6/2026 by MarketBeat.com Staff. From Our PartnersPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredGet your evenings backThe Instant Scanner delivers the night's qualifying setups with exact buy prices and defined exits, in minutes...Profits Run | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredIntel Shares Jumped 177% After Elon Musk's DealElon Musk's April 2026 partnership with Intel sent shares climbing 177% within two months. Jeff Brown, the ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iterum Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Iterum Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.